Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Expected to Announce Quarterly Sales of $59.77 Million
Equities analysts forecast that Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) will post $59.77 million in sales for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Vanda Pharmaceuticals’ earnings, with estimates ranging from $57.10 million to $64.00 million. Vanda Pharmaceuticals posted sales of $53.04 million in the same quarter last year, which would indicate a positive year over year growth rate of 12.7%. The business is scheduled to issue its next earnings results on Wednesday, February 12th.
According to Zacks, analysts expect that Vanda Pharmaceuticals will report full-year sales of $225.97 million for the current year, with estimates ranging from $223.40 million to $230.00 million. For the next year, analysts forecast that the company will report sales of $274.20 million, with estimates ranging from $245.50 million to $327.10 million. Zacks’ sales averages are an average based on a survey of sell-side research firms that follow Vanda Pharmaceuticals.
Several research firms recently weighed in on VNDA. BidaskClub lowered Vanda Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, February 1st. Stifel Nicolaus restated a “hold” rating on shares of Vanda Pharmaceuticals in a report on Sunday, February 2nd. ValuEngine upgraded Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, January 3rd. Citigroup lowered Vanda Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $19.00 target price for the company. in a report on Thursday, November 7th. Finally, Zacks Investment Research lowered Vanda Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, February 8th. Two equities research analysts have rated the stock with a sell rating and five have issued a hold rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $19.40.
In other Vanda Pharmaceuticals news, CFO James Patrick Kelly sold 4,020 shares of Vanda Pharmaceuticals stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $15.94, for a total value of $64,078.80. Following the transaction, the chief financial officer now directly owns 205,726 shares of the company’s stock, valued at approximately $3,279,272.44. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Mihael Hristos Polymeropoulos sold 9,467 shares of Vanda Pharmaceuticals stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $16.00, for a total value of $151,472.00. Following the completion of the transaction, the chief executive officer now directly owns 1,234,579 shares in the company, valued at $19,753,264. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 14,642 shares of company stock valued at $234,100. Corporate insiders own 8.20% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the business. PNC Financial Services Group Inc. increased its position in Vanda Pharmaceuticals by 74.9% in the 4th quarter. PNC Financial Services Group Inc. now owns 3,073 shares of the biopharmaceutical company’s stock worth $50,000 after buying an additional 1,316 shares during the period. Quantbot Technologies LP increased its position in Vanda Pharmaceuticals by 28.7% in the 4th quarter. Quantbot Technologies LP now owns 5,200 shares of the biopharmaceutical company’s stock worth $85,000 after buying an additional 1,159 shares during the period. Meeder Asset Management Inc. increased its position in Vanda Pharmaceuticals by 1,638.3% in the 3rd quarter. Meeder Asset Management Inc. now owns 5,215 shares of the biopharmaceutical company’s stock worth $69,000 after buying an additional 4,915 shares during the period. Amalgamated Bank bought a new position in Vanda Pharmaceuticals in the 4th quarter worth approximately $165,000. Finally, Victory Capital Management Inc. increased its position in Vanda Pharmaceuticals by 25.7% in the 4th quarter. Victory Capital Management Inc. now owns 10,190 shares of the biopharmaceutical company’s stock worth $167,000 after buying an additional 2,084 shares during the period. 99.50% of the stock is currently owned by institutional investors.
About Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.
See Also: Cost of Debt
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.